Abstract Purpose: To assess adherence of non-pharmaceutically sponsored trials (non-PSTs) to ICH protocol structure guidelines and to estimate the effect of implementing Institutional Review Board's (IRB) review on this adherence. Methods: This is a retrospective exploratory study where 60 non-PST clinical trial protocols (CTPs) were reviewed and halved to IRB-reviewed CTPs (IRCTPs) and non-IRB-reviewed CTPs (non-IRCTPs). Adherence score (AS) was calculated as the number of fulfilled items or sub-items divided by their total number. Results: Three adherence patterns were encountered: (1) items consistently present in both groups e.g. general and background information, objectives, inclusion criteria and intervention details, (2) items consistently absent in both groups and included contact information of investigators and trial sites, product accountability, randomization codes' management, interim analyses and many other statistical aspects, and (3) items variably present in both groups where the effect of IRB was verifiable. Trial site details, potential benefits, discontinuation and exclusion criteria, and follow up for adverse events were more encountered in IRCTPs than non-IRCTPs. Withdrawal criteria and 
Introduction
To protect rights, safety, dignity and well-being of research participants, a trial should only start after its detailed protocol is reviewed by an independent ethics committee (IEC) [1] . The clinical trial protocol (CTP) is an essential component of any study that serves both as an operation manual and as an explanatory document. It should specify which patients are eligible, which treatments are to be evaluated, and how each patient's response is to be assessed. CTP is not aimed to be a rigid straight jacket preventing interesting or unexpected findings, but rather a well-organized piece of thought regarding a specific hypothesis [2] .
As suggested by the International Conference on Harmonization document ''Guidelines for Good Clinical Practice, ICH E6(R1)'', a list of 16 items that should be included in any CTP that impacts safety and well-being of human subjects and intends to be submitted to regulatory authorities in the European Union, Japan, and the United States [3] . Failure to comply with GCP guidelines can lead to exclusion of questionable data, restriction/exclusion of violators and notification of those affected by the violators to take the appropriate actions [4] . This drives pharmaceutical companies to allocate sufficient resources, manpower and expertise that can effectively manage trails either directly or via outsourcing.
Non-pharmaceutically sponsored trials (NPSTs), unless adequately funded and sufficiently staffed by experienced personnel such as the setting of cooperative groups, can face great difficulties to comply with applicable regulations and guidelines. Academic institutions that treat patients, educate students and do research struggle to comply with research-governing regulations and guidelines because their resources and manpower are spanned over these three domains.
It is not known whether oncology CTPs in academia outside ICH jurisdictions adhere to ICH protocol guidelines. In addition, it is not clear if adherence to ICH guidelines is affected by whether the protocol is reviewed by an Independent/Intuitional Review Board (IRB) or not.
Aims of the study
To assess whether CTPs of NPSTs at the Egyptian National Cancer Institute (NCI-Egypt) adhere to the unified standard protocol format suggested by ICH and to assess whether adherence is affected by the protocol being reviewed by the local IRB or not.
Methods

Design and setting
This is an exploratory retrospective study of the before-andafter design. It was conducted at the Egyptian National Cancer Institute (NCI-Egypt), Cairo University (CU). NCI-Egypt is the largest center in the Middle East devoted to cancer treatment, education, and research [5] .
CTP identification
At NCI-Egypt, there are no databases for study protocols. However, an official copy of academic protocols is usually kept in the student's file in the Higher Education Affairs. Access to these protocols is very limited. We got the Higher Administration approval to access these protocols for the purpose of research. As we are assessing CTPs, we limited our criteria to the clinical departments.
Inclusion criteria
CTPs were included if they referred to NPSTs and started accrual after the release of ICH E6(R1) guidelines that contain the section on protocol structure in 1996 [3] . IRB review of NPST protocols was mandated by NCI-Egypt in the year 2008. We included the immediate 30 CTPs prior the mandate of IRB review and the immediate 30 CTPs following that mandate (i.e. a total of 60 CTPs).
Data collection and calculation of adherence scores (AS)
The ICH GCP protocol structure guidelines were mentioned explicitly in section number 6. It contains 16 items and each is further divided into several sub-items [3] . These were transformed into a paper CRF (Appendix 1). Each sub-item was scored (1) if fulfilled, (0) if missing or (NA) if non-applicable and in the latter case it was not scored and was excluded from calculations. The adherence score of every major item (item AS) is the sum of the scores of individual sub-items divided by the total number of sub-items · 100. The total adherence score of a protocol (protocol AS) is the sum of individual items' score divided by the total number of items (i.e. 16) · 100. The 16 items were categorized into 3 groups: scientific, ethical and administrative. The first includes ICH items 6.2-6.6, the second includes item 6.12 only and the third includes the rest of items [6] . The scientific, ethical and administrative score is the sum of items in the group divided by their total number · 100. Thus; individual item, scientific, ethical, administrative and protocol scores range between 0 and 100.
Statistical analysis
Most sub-items were categorical variables. Adherence scores were continuous variables. CTPs were divided into two groups; IRB-reviewed CTPS (IRCTPs) and non-IRB-reviewed CTPs (non-IRCTPs). Categorical variables were presented as percentages and Chi squared test used to assess the difference between different groups. Numerical variables were presented as means and standard deviations (SD) or Medians and interquartile ranges (IQRs) and group differences as t-tests. A probability (p value) < 0.05 was considered statistically significant.
Paper CRFs were transcribed to SPSSÒ software program, version 15 (Chicago, USA). All analyses were done using the appropriate statistical function in the program.
Results
The characteristics of the 60 CTPs included in the current study are shown in Table 1 . Assessment of compliance of academic oncology CTPs to ICH protocol items (Appendix 1) showed three patterns: always-fulfilled, always-missing and variable. The always-fulfilled items included most of the general and background information, objectives and purpose, inclusion criteria and details of the intervention ( Table 2 ). The always-missing items included the contact information of individuals and sites included in the trials, the trial stopping rules, product accountability, randomization code management, source data to be directly recorded in the CRFs, interim analyses, statistical criteria for trial termination, managing missing data and protocol deviations, record keeping, finance and insurance, and publication policy ( Table 3 ). The third pattern was the items that varied from one protocol to another. These include the rest of items. Fulfillment of items in this category ranged from 3% to 97% (Table 4 ). For the whole 60 CTPs the mean adherence scores of the 16-items ranged between 0% and 100% (Table 5 ). The mean total, administrative, ethical and scientific scores were 41%, 19%, 52% and 54%, respectively.
The possible impact of IRB review could only be verified for the variable items and not the always-fulfilled or alwaysmissing items. Items like trial site details, benefits to subjects, exclusion criteria, subjects' follow up after adverse events, and ethical considerations were significantly better for IRCTPs compared to non-IRCTPs. Items like stopping rules, withdrawal criteria for individual subjects and monitoring of treatment compliance were significantly better in the non-IRCTPs. The rest of items in this third pattern were not different in the IRCTPs compared to the non-IRCTPs (Table 4) . Regarding individual items' AS, the general information score, treatment score, ethics score were significantly higher for IRCTPs than non-IRCTPs. Data handling was significantly better in the non-IRCTPs. The rest of items were not statistically different in the two groups (Table 5) . When items were categorized, ethical, administrative and protocol AS were significantly better for the IRCTPs than non-IRCTPs. Meanwhile, the scientific score was similar in both groups.
Discussion
Our study, as we believe, is the first to address the issue of compliance of oncology CTPs to the ICH guidelines for protocol structure in academia outside ICH boundaries. At NCI-Egypt, academic CTPs are developed by post-graduate students under supervision of NCI teaching staff or by the teaching staff themselves in the concerned departments. As expected, the scientific part of the protocol was well developed in the majority of the protocols. This is confirmed in our trial where the background information (literature search), objectives and purpose, inclusion criteria and description of study treatments are always fulfilled in all of the reviewed protocols. However as most of the trials were from the clinical departments and there were no phase I trials, preclinical data were missing in most of the protocols. This should not be the case and preclinical data are very important and needs inclusion in every protocol at least in a concise manner.
Researcher enthusiasm and, may be, bias in favor of the experimental intervention is reflected in lack of consideration of early study termination through interim analysis, failure to mention subject withdrawal criteria in 88%, mentioning potential benefits in 77% and risks in only 38%, inclusion of safety assessment in 75%, and anticipating adverse events and stating the tools to record them in only 33% of protocols. While this enthusiasm is good, it should be trimmed and should not obscure the potential harms and the researcher should be prepared to deal with harms if they occur. Involvement of the statistician very early in the study design is not a common practice at the NCI-Egypt. This is reflected in the reviewed protocols through unspecified design and statistical methods in 20% and 47% respectively, lack of justification for the chosen sample size in 56%, failure to mention the significance level and the analysis set in 53% and 92% respectively, non-adoption of interim analysis and non-specification of statistical criteria for trial termination, and lack of consideration of how missing and spurious data and protocol deviations will be dealt with. However, this practice should be discouraged and the statistician should be an integral member of any research team from the early phase of trial design.
Academic trials at NCI-Egypt are largely dependent on the researcher with little support from research nurses, data managers, trial coordinators, monitors or trial pharmacists. Moreover, structured training in research methods and data collection is lacking. This is reflected in the reviewed protocols by the lack of consideration of data handling, access to source data, record keeping and the rare inclusion of CRFs as supplements to the protocols. Also quality assurance and control were not considered. This situation clearly points to how overburdened are the researchers at NCI-Egypt and the need for their support to better manage the trials for better quality and more productivity. Setting a research center that provides this support and training to different members of the research team in all trial related activities as well as monitoring of academic trial conduct is eagerly needed. The identification of any data to be recorded directly on the CRFs, and considered to be source data 9. Statistics 9.1. Timing of any planned interim analysis 9.4. Criteria for the termination of the trial 9.5. Procedure for accounting for missing, unused, and spurious data 9.6. Procedures for reporting any deviation(s) from the original statistical plan 10. Direct access to source data/documents 11. Quality assurance and control 13. Record keeping 14. Financing and insurance 15. Publication policy
The consent process was significantly more encountered for the IRCTPs than the non-IRCTPs. However, ethical considerations that pertain to clinical trials are many and are not limited to the informed consent. They include, among many other issues, trial specific issues like randomization, placebo use, vulnerability, and selection criteria. Apart from the consent, none of these issues were considered from ethical view point whenever relevant. None of the 8 pediatric trials mentioned the issue of assent. This highlights the urgent need to train researchers in research ethics. While it is mandatory for any IRB to review the consent, the consent was mentioned in the IRB-reviewed protocol in 70% of cases. This may mean that the IRB members do not insist that written consent is mentioned as an inclusion criterion. General information regarding contact information (address and telephone) of trial personnel, sites and laboratories were lacking. We think that this reflects the concept that these trials are conducted exclusively in NCI-Egypt. However, this is not a plausible reason for missing this information at least to ease communication when needed.
Financing and insurance issues were lacking in all protocols. Despite all trials are sponsored by NCI-Egypt, no budgets were included. However, researchers were not compensated for the significant time and efforts spent during trials. Moreover, they may spend out-of-pocket money to cover issues like computer edits, data entry and analysis. This attitude should be changed and researchers should be trained and offered support to develop a budget of every trial. This budget should include all aspects to avoid researcher's out-of-pocket payments. Trial insurance is lacking at NCI-Egypt. While no issues of subject compensation were raised so far, this could happen at any time and the higher NCI-Egypt administration should be careful about this issue as it may be disastrous.
Record keeping was not discussed in any of the protocols. Source documents are managed according to the routine NCI-Egypt practices. However, research documents lack clear guidelines regarding how and for how long they should be kept. Publication policy was not mentioned in any of the protocols and there are no guidelines regarding this issue at NCIEgypt and these need consideration to avoid conflicts that may arise when publications are done after trial completion.
The implementation of the mandatory IRB review of CTPs at NCI-Egypt in 2008 was associated with significantly higher scores for ethics, treatment details and general protocol information. When grouped, the beneficial effects were noticed in the ethical and administrative group of items. This can be a direct effect of the review process with these parameters forming the main focus of review. The scientific score was similar in both IRCTPs and non-IRCTPs. This reflects the reasonable scientific content of all protocols. Moreover, science is not the main focus of an IRB review as this was left for the concerned clinical department.
Items like background information, trial objectives, assessment of efficacy and safety, and trial design were equally good for IRCTPs and non-IRCTPs with no significant differences. However, items like subject selection and withdrawal, statistics, access to source data, quality assurance and control, financing and insurance and publication policy were equally bad for IRCTPs and non-IRCTPs with no significant differences. These need to be included in researcher training and awareness as well as in the institution guidelines and policies. Total protocol adherence score was significantly better for IRCTPs and non-IRCTPs (43% vs. 38%, respectively, p 0.003) mainly due to improvement of the ethical parts (from 70% vs. 33%, p 0.004) and administrative parts (from 22% vs. 16%, p < 0.001). However, this is far beyond a desirable level.
Our results are similar to that of single institution study from Spain that reviewed the quality of protocols submitted to a newly developed IEC where the most frequent deficiencies were related to statistical analysis, patient selection criteria, choice of sample size, concomitant medication, monitoring of adverse events, compliance of subjects and experimental design. Lack of insurance for the people and institutions involved, and inadequacies in the investigators' brochure and case report forms were also encountered. However, the difference in percentage of deficiency reflects time and settings variance [7] . Moreover, their assessments were based on a checklist that relied on published criteria and personal experience. They came to the conclusion that multidisciplinary teams should be included in the design of protocols.
Our study has some limitations. It is retrospective and in the setting of one academic institution in the field of oncology. However, we believe that it was very difficult if we were to conduct this study in a prospective fashion as it would take a very long time with no or little difference in the outcome. Moreover, retrospective studies accurately reflect the community practice and needs fewer resources than prospective ones [8] . The second limitation of our study is that it involved CTPs from academic trials excluding pharmaceutically sponsored ones. This limits the generalizability of our findings to nonacademic trials. However, we do believe that pharma has cut a long way in complying with regulations and guidelines. They have the resources and expertise to ensure compliance directly through their own staff or indirectly through outsourcing. More importantly is the motivation; if they are not to comply, their application for an approval of a new drug or device may be rejected. This is not the case in academia where motivation, expertise and the resources are less. So, most of the time, academia needs support to comply with rules and regulations. The third limitation is that our study was limited to the field of oncology and included only one center, NCI-Egypt. However, cancer is the most researched disease; a review of research protocols submitted to local IECs in Italy revealed that cancer trials represented 23% of all trials with breast cancer being the most researched topic [9] . Limited accessibility to clinical research data in Egypt is prevalent. Unlike the US National Institute of Health trial registry like that of clinicaltrials.gov [10] , trials in Egypt are not registered in a publicly accessible way and the protocols are mostly considered confidential. Thus, it would be difficult to access data from outside the institute in which the researcher is working where he can get the permission to review the protocols through personal communication with the higher institutional administration and to explain the research in detail.
Selection and assessment of CTPs for adherence to ICH protocol guidelines were carried out by a single researcher with the potential for bias. Ideally, such bias would be overcome when two independent reviewers assess CTP quality. However, to limit the selection bias, all consequent CTPs that immediately preceded and followed the mandate of IRB review were included.
This study adopted the before-and-after design [11] . Despite the ethical and administrative sections of CTPs had improved during the period following the mandate of IRB review compared to the preceding period, we cannot infer a causal relationship as the study was observational.
Recommendations and outcomes of this study
The ICH E6(R1) guidelines for CTPs can serve as a good explanatory document that can help academic researchers in writing their study protocols. Based on this document together with some modifications to suit the NCI-Egypt peculiarities, we have developed a CTP template and made it available for comments of NCI researchers then it will be publicly available through the NCI-Egypt website and may be adopted as the mandate template. The CRF we developed may be used as a checklist to be completed by the researchers to assure that their protocol was thought of from all aspects. It can also be used by research committees to assess protocol quality.
The difficulties we faced with accessing CTPs ignited the proposal for registering trials in a specific electronic database that can be publicly available through NCI-Egypt website. Old CTPs will be scanned and uploaded as well. When completed, this NCI-Egypt trial registry will include almost all academic CTPs performed at this institution.
Given the utmost importance of the protocol in any study, we propose that formal training on protocol writing skills be conducted regularly at NCI-Egypt with input from epidemiologists/biostatisticians, ethicists, data managers as well as the relevant departments. This training will provide both the theoretical background for the topic and also will guide the researchers while preparing their own protocols.
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